
Arthroplasty
Low- and high-dose TXA effective in reducing blood loss and transfusion needs in TKA
BMC Musculoskelet Disord. 2013 Dec 5;14:340. doi: 10.1186/1471-2474-14-340135 patients scheduled for total knee arthroplasty were randomized to three different hemostasis protocols with 2 hour postoperative drain clamping: 1) a 250mg intra-articular tranexamic acid (IA-TXA) injection (low-dose), 2) a 500mg IA-TXA injection (high-dose), or 3) a placebo injection. The purpose was to determine the effect of different TXA doses on reducing blood loss and transfusion needs. The results indicated that both TXA doses significantly reduced calculated blood loss and transfusion requirements compared to the placebo group. Furthermore, blood loss was similar between TXA groups, although fewer transfusions were needed in those who received 500mg TXA. The latter of the two findings may have been impacted by significantly lower preoperative hemoglobin levels in the 250mg TXA group.
Unlock the full article
Get unlimited access to OrthoEvidence with a free trial
Start TrialCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or continue reading this full article
Register Now

Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.